Powerfully Personal.
The first immunotherapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
Targeted immune response: PROVENGE starts with your patient’s own immune system and activates his antigen-presenting cells (APCs) to help the immune system target and attack prostate cancer cells.1,2
SEE THE SCIENCE BEHIND PROVENGE >>
PIONEERS OF IMMUNOTHERAPY
PROVENGE is the first FDA-approved immunotherapy using the patient’s own immune system to fight advanced prostate cancer. Studies suggest that men who receive PROVENGE when their PSA level is lower live longer.3,4
LEARN HOW PROVENGE MAY PROLONG SURVIVAL >>

THE IMPORTANCE OF PATIENT IDENTIFICATION
Early identification of men with mCRPC who are indicated for PROVENGE is key to achieving optimal clinical benefit. Almost 25% of men assumed to have nonmetastatic CRPC were found to have metastatic disease when screened via imaging.5
According to the National Comprehensive Cancer Network® (NCCN®), sipuleucel-T (PROVENGE) may be considered for men with mCRPC if they didn't receive it as initial therapy.6
According to the National Comprehensive Cancer Network® (NCCN®), sipuleucel-T (PROVENGE) may be considered for men with mCRPC if they didn't receive it as initial therapy.6